CR20140175A - Compuestos y métodos para mejorar las respuestas inmunitarias innatas - Google Patents

Compuestos y métodos para mejorar las respuestas inmunitarias innatas

Info

Publication number
CR20140175A
CR20140175A CR20140175A CR20140175A CR20140175A CR 20140175 A CR20140175 A CR 20140175A CR 20140175 A CR20140175 A CR 20140175A CR 20140175 A CR20140175 A CR 20140175A CR 20140175 A CR20140175 A CR 20140175A
Authority
CR
Costa Rica
Prior art keywords
methods
compounds
immune responses
innate immune
improve innate
Prior art date
Application number
CR20140175A
Other languages
English (en)
Inventor
Anna Lindsey Banka
Janos Botyanszki
Eric Gregory Burroughs
John George Catalano
Wendy Huang Chern
Hamilton Dickson
Margaret J Gartland
Robert Hamatake
Hans Hofland
Jesse Daniel Keicher
Christopher Brooks Moore
John Bradford Shotwell
Matthew David Tallant
Jean-Philippe Therrien
Shihyun You
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR20140175A publication Critical patent/CR20140175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporcionan ciertos compuestos y las sales farmacéuticamente aceptables de los mismos, sus composicionesfarmacéuticas, sus métodos de preparación, y su uso para eltratamiento de infecciones virales.
CR20140175A 2011-10-21 2014-04-21 Compuestos y métodos para mejorar las respuestas inmunitarias innatas CR20140175A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23

Publications (1)

Publication Number Publication Date
CR20140175A true CR20140175A (es) 2014-06-03

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140175A CR20140175A (es) 2011-10-21 2014-04-21 Compuestos y métodos para mejorar las respuestas inmunitarias innatas

Country Status (22)

Country Link
US (1) US20140249143A1 (es)
EP (1) EP2768506A4 (es)
JP (1) JP2014532626A (es)
KR (1) KR20140094559A (es)
CN (1) CN103957910A (es)
AR (1) AR088793A1 (es)
AU (1) AU2012325971B2 (es)
BR (1) BR112014008727A2 (es)
CA (1) CA2851801A1 (es)
CL (1) CL2014001016A1 (es)
CO (1) CO6910198A2 (es)
CR (1) CR20140175A (es)
DO (1) DOP2014000081A (es)
EA (1) EA201490610A1 (es)
IL (1) IL231894A0 (es)
MX (1) MX2014004814A (es)
PE (1) PE20141359A1 (es)
SG (2) SG11201400988SA (es)
TW (2) TW201542567A (es)
UY (1) UY34406A (es)
WO (1) WO2013059559A2 (es)
ZA (1) ZA201402392B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
WO2016053893A1 (en) * 2014-09-29 2016-04-07 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
CN110709400A (zh) 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式
US20210347777A1 (en) 2018-10-23 2021-11-11 Basf Se Tricyclic pesticidal compounds
CN114732823B (zh) * 2019-03-13 2023-05-23 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
AU2021256876A1 (en) 2020-04-14 2022-11-03 Basf Se Tricyclic pesticidal compounds
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンｋｒａｓ阻害剤
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE441449B (sv) * 1979-02-09 1985-10-07 Roussel Uclaf Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
RU2310657C2 (ru) * 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2416488B1 (en) * 2009-03-31 2019-03-06 Daikin Industries, Ltd. Electrode film for polymer actuator element, and polymer actuator element comprising same
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
ZA201402392B (en) 2017-09-27
US20140249143A1 (en) 2014-09-04
JP2014532626A (ja) 2014-12-08
CA2851801A1 (en) 2013-04-25
AR088793A1 (es) 2014-07-10
EP2768506A4 (en) 2015-08-19
AU2012325971B2 (en) 2016-03-31
CO6910198A2 (es) 2014-03-31
WO2013059559A2 (en) 2013-04-25
EA201490610A1 (ru) 2014-09-30
KR20140094559A (ko) 2014-07-30
TW201542567A (zh) 2015-11-16
CN103957910A (zh) 2014-07-30
SG10201505664WA (en) 2015-09-29
EP2768506A2 (en) 2014-08-27
DOP2014000081A (es) 2014-07-15
PE20141359A1 (es) 2014-10-13
WO2013059559A3 (en) 2013-11-14
AU2012325971A1 (en) 2014-04-17
UY34406A (es) 2013-05-31
IL231894A0 (en) 2014-05-28
MX2014004814A (es) 2014-05-27
BR112014008727A2 (pt) 2017-04-25
TW201333003A (zh) 2013-08-16
SG11201400988SA (en) 2014-07-30
CL2014001016A1 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
EA201490947A1 (ru) Производные пурина для лечения вирусных инфекций
UY34262A (es) Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
EA201491486A1 (ru) Производные пиперидинопиримидина для лечения вирусных инфекций
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CR20150549A (es) Compuestos heterocíclicos y sus usos
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
CO6791618A2 (es) Derivados de nucleósidos 2-sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales
NI201400108A (es) Compuestos de heterociclilo
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CO7020872A2 (es) Agentes de arn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
ECSP14013215A (es) Compuestos novedosos
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos